Page last updated: 2024-10-16

carbamates and Depression, Endogenous

carbamates has been researched along with Depression, Endogenous in 7 studies

Research Excerpts

ExcerptRelevanceReference
"Depressed individuals (N=45) with elevated levels of anhedonia were assigned to a 5-week treatment period with ezogabine (900 mg/day; N=21) or placebo (N=24)."5.41Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. ( Bagiella, E; Bevilacqua, L; Chadha, N; Collins, KA; Corniquel, M; Costi, S; Han, MH; Hoch, M; Iosifescu, DV; Iqbal, T; Jha, MK; Kirkwood, KA; Mathew, SJ; Morris, LS; Murrough, JW; Parides, MK; Pizzagalli, DA; Salas, R; Stern, ER; Swann, AC; Ursu, S; Vo-Le, B; Whitton, A, 2021)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19902 (28.57)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's2 (28.57)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Costi, S1
Morris, LS1
Kirkwood, KA1
Hoch, M1
Corniquel, M1
Vo-Le, B1
Iqbal, T1
Chadha, N1
Pizzagalli, DA1
Whitton, A1
Bevilacqua, L1
Jha, MK1
Ursu, S1
Swann, AC1
Collins, KA1
Salas, R1
Bagiella, E1
Parides, MK1
Stern, ER1
Iosifescu, DV1
Han, MH1
Mathew, SJ1
Murrough, JW1
Carnevali, L1
Vacondio, F1
Rossi, S1
Callegari, S1
Macchi, E1
Spadoni, G1
Bedini, A1
Rivara, S1
Mor, M1
Sgoifo, A1
Vinod, KY1
Xie, S1
Psychoyos, D1
Hungund, BL1
Cooper, TB1
Tejani-Butt, SM1
Eroglu, A1
Kucuktulu, U1
Erciyes, N1
Turgutalp, H1
ANTON, A1
DONNADIEU, JM1
BRADITCH, JL1
Guilarte, TR1
Hammoud, DA1
McGlothan, JL1
Caffo, BS1
Foss, CA1
Kozikowski, AP1
Pomper, MG1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Developing Neuronal KCNQ Channel Modulators for Mood Disorders[NCT03043560]Phase 245 participants (Actual)Interventional2017-09-25Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS)

A measure specifically designed to assess hedonic capacity for social and interpersonal pleasure.The ACIPS is a 17-item self-report measure scored on a likert scale, ranging from 1 (very false for me) to 6 (very true for me). Full scale from 17-102, higher score indicates higher hedonic capacity (NCT03043560)
Timeframe: baseline and 5 weeks

,
Interventionscore on a scale (Mean)
baseline5 weeks
Ezogabine46.165.1
Placebo53.759

Change in Snaith-Hamilton Pleasure Scale (SHAPS)

"The SHAPS is a well-validated 14-item self-report questionnaire commonly used to assess anhedonia. Each item on the SHAPS is worded so that higher scores indicate greater pleasure capacity. A total score can be derived by summing the responses to each item. Items answered with strongly agree are coded as 1, while a strongly disagree response was assigned a score of 4. Total scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia." (NCT03043560)
Timeframe: baseline and 5 weeks

,
Interventionscore on a scale (Mean)
Baseline5 weeks
Ezogabine38.727.5
Placebo33.730

Change in Ventral Striatum (VS) Activation

"change in activation during reward anticipation within the bilateral VS from baseline (Study Visit 0) to the primary outcome visit (Study Visit 5) as measured by functional MRI during the incentive flanker task (IFT). The IFT, like the Monetary Incentive Delay task, permits discrete modeling of brain activity during anticipation of an incentive.~Functional scans were preprocessed and denoised for motion and physiological noise using multi-echo independent component analysis (ME-ICA). Task-based modeling was conducted using AFNI and FSL software. The primary outcome for reward anticipation was the contrast of reward cue compared to neutral cue (reward>neutral cue). The primary imaging outcome was analyzed using a linear mixed model with a single random intercept term treating time as discrete or continuous as appropriate." (NCT03043560)
Timeframe: baseline and 5 weeks

,
InterventionBold Oxygen-level Dependent (BOLD) Signa (Mean)
baseline5 weeks
Ezogabine-0.260.176
Placebo0.950.015

Clinical Global Impression - Improvement (CGI-I)

A widely administered clinician rated global measure of the degree of improvement from the initial assessment in subject overall illness severity. 7 point scale rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT03043560)
Timeframe: baseline and 5 weeks

,
Interventionscore on a scale (Mean)
baseline5 weeks
Ezogabine42.1
Placebo42.8

Clinical Global Impression - Severity (CGI-S)

Clinician rated global measure of subject overall illness severity. a 7-point scale rated as 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. (NCT03043560)
Timeframe: baseline and 5 weeks

,
Interventionscore on a scale (Mean)
baseline5 weeks
Ezogabine4.42.6
Placebo4.63.3

Montgomery-Asberg Depression Rating Scale (MADRS)

A 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression). (NCT03043560)
Timeframe: baseline and 5 weeks

,
Interventionscore on a scale (Mean)
baseline5 weeks
Ezogabine28.312.7
Placebo26.818.5

Specific Loss of Interest and Pleasure Scale (SLIPS)

The SLIPS is a recently developed and validated measure of anhedonia that is tailored to detect recent changes in anhedonia. A 23-item measure, each item range from 0-3. Full scale from 0 to 69, higher score indicates more recent changes. (NCT03043560)
Timeframe: baseline 5 weeks

,
Interventionscore on a scale (Mean)
baseline5 weeks
Ezogabine32.316.3
Placebo28.821.5

Temporal Experience of Pleasure Scale (TEPS)

The TEPS is composed of 18-items rated on a likert-type scale ranging from 1 (Very True for me) to 6 (Very False for me), and yields two subscales. Ten items make up the TEPS-Anticipatory Pleasure (TEPS-ANT) scale with a range from 10 (not motivated) to 60 (highly motivated). The other eight TEPS items make up the TEPS-Consummatory Pleasure (TEPS-CON) scale; range from 8 (not responsive) to 48 (highly responsive). Total scores range is 18-108. Lower scores indicate greater levels of anhedonia. (NCT03043560)
Timeframe: baseline and 5 weeks

,
Interventionscore on a scale (Mean)
TEPS-ANT baselineTEPS-ANT 5 weeksTEPS-CON baselineTEPS-CON 5 weeks
Ezogabine26.337.324.832.2
Placebo28.632.425.629.9

World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)

A 12-item generic assessment instrument that measures the level of functioning. Each item is scored from 0 to 4 and the items are summed to provide a total score. The score therefore ranges from 0 to 48, with higher scores indicating greater disability. (NCT03043560)
Timeframe: baseline and 5 weeks

,
Interventionscore on a scale (Mean)
baseline5 weeks
Ezogabine15.510.2
Placebo16.511.6

Trials

1 trial available for carbamates and Depression, Endogenous

ArticleYear
Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial.
    The American journal of psychiatry, 2021, 05-01, Volume: 178, Issue:5

    Topics: Adult; Anhedonia; Carbamates; Depressive Disorder; Depressive Disorder, Major; Double-Blind Method;

2021

Other Studies

6 other studies available for carbamates and Depression, Endogenous

ArticleYear
Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2015, Volume: 25, Issue:11

    Topics: Amidohydrolases; Anhedonia; Animals; Antidepressive Agents; Arrhythmias, Cardiac; Biphenyl Compounds

2015
Dysfunction in fatty acid amide hydrolase is associated with depressive-like behavior in Wistar Kyoto rats.
    PloS one, 2012, Volume: 7, Issue:5

    Topics: Amidohydrolases; Animals; Arachidonic Acids; Benzamides; Brain; Brain-Derived Neurotrophic Factor; C

2012
Multiple dose-activated charcoal as a cause of acute appendicitis.
    Journal of toxicology. Clinical toxicology, 2003, Volume: 41, Issue:1

    Topics: Acute Disease; Adult; Antidotes; Appendicitis; Appendix; Carbamates; Charcoal; Depressive Disorder;

2003
[Gamaquil (gamma-phenylpropylcarbamate) in neurological practice].
    Die Medizinische Welt, 1963, Mar-23, Volume: 12

    Topics: Anti-Anxiety Agents; Carbamates; Depression; Depressive Disorder; Muscular Diseases; Neurotic Disord

1963
[Trial use of cyclarbamate in obstetrics].
    Revue francaise de gynecologie et d'obstetrique, 1963, Volume: 58

    Topics: Carbamates; Depression; Depressive Disorder; Female; Humans; Hyperemesis Gravidarum; Muscle Relaxant

1963
Dysregulation of glutamate carboxypeptidase II in psychiatric disease.
    Schizophrenia research, 2008, Volume: 99, Issue:1-3

    Topics: Adult; Aged; Autoradiography; Bipolar Disorder; Carbamates; Depressive Disorder; Dominance, Cerebral

2008